Rigosertib — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	1	12	—	—	2006-06
Leukemia	Phase3	Phase 3	1	4	—	—	2010-07
Malignant Anal Neoplasm	Phase2	Phase 2	0	1	—	—	2013-03
Malignant Cervical Neoplasm	Phase2	Phase 2	0	1	—	—

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS KRAS4A1
KG5 + RigosertibSubstitutes

Clinical trials

Trials with this intervention (12)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–12 of 12 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05764395	Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors	terminated	Phase 2	7	Vanderbilt-Ingram Cancer CenterOTHER	1	Sep 16, 2026	clinicaltrials
NCT04177498	Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC	completed